Treatment of resistance to Tafasitamab

Tafasitamab (Tafasitamab) is a prescription medicine used with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) who have come back (relapsed) or failed to respond to previous treatments (refractory) and who are unable to receive a stem cell transplant. It is not known whether tafracetamab is safe and effective in children.

Tafaracetamumab is a monoclonal antibody that targetsCD19 antigen. Sometimes patients may develop resistance to tafaracetamumab. Understanding the mechanism of resistance is crucial to finding more effective treatment options. Through molecular and genetic studies of drug-resistant cells, new therapeutic targets can be discovered or specific drugs targeting drug resistance mechanisms can be developed. Resistance can be overcome by increasing the dose of tafracetamumab, but this needs to be done under the guidance of a physician and with the patient closely monitored for response and side effects. If drug resistance cannot be overcome by the above methods, other treatment options can be considered, which may include participating in clinical trials to trial other new anti-cancer drugs or personalized treatments.

Talfaracetam's single-origin generic drug has not yet been launched in the country, so it is not included in medical insurance. There are European and American versions of Tafaracetam's single-antigen drugs marketed overseas. The American version's specificationsThe price per box of 200 mg may be around 20,000 yuan, and the price of the European version's 200 mg box may be around 10,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same, but the price is more expensive. Currently, there is no generic version of Tafaracetam on the market. For more drug information and specific prices, please consult a medical consultant.